RBCC Partner n3D’s Innovative Toxicity Test Highlighted In Major Scientific Journal

HENDERSON, Nev.--(BUSINESS WIRE)--Rainbow Coral Corp. (OTCBB:RBCC) partner n3D has just had an important manuscript about 3D bioprinting and cell culture screenings published in the journal Scientific Reports, a Nature publication.

“A Spheroid Toxicity Assay Using Magnetic 3D Bioprinting and Real-Time Mobile Device-Based Imaging”

The article, entitled “A Spheroid Toxicity Assay Using Magnetic 3D Bioprinting and Real-Time Mobile Device-Based Imaging” describes how scientists at n3D have devised a novel assay (or test) for using 3D bioprinted cell aggregates (also known as spheroids). n3D President and Chief Science Officer Glauco Souza Ph.D. was one of the 12 co-authors on the article.

“This assay can detect the toxic effects of drugs with both accuracy and high volume to meet the needs of researchers in drug discovery and development for fast and robust models,” Dr. Souza said. “In contrast to other 3D bioprinting technologies, because of its simplicity, n3D's technology is accessible to just about any laboratory working with cells. This will go a long way in satisfying the growing demand for such tests in drug development. There is a great potential here, both in terms of further research and commercial applications.”

RBCC CEO Kimberly Palmer added, “Having this paper published shows the level of n3D’s expertise in this field and gives them additional credibility and validity. We’ve been quite pleased with our partnership with n3D and look forward to their next bioprinting innovation. There will be a substantial market for this latest breakthrough and we’ll work closely with n3D to get it to the marketplace.”

For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.

About Rainbow Biosciences

Rainbow Biosciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.